Urine Omics Predicting IO Therapy Responses in mRCC Patients
NCT04712305
·
clinicaltrials.gov ↗
RECRUITING
Status
400
Enrollment
OTHER
Sponsor class
Conditions
Metastatic Renal Cell Carcinoma
Interventions
OTHER:
No intervention required
Sponsor
National Taiwan University Hospital